Krka
ISIN: SI0031102120 | Ticker: KRKG | LEI: 549300H9RLRTRTLRUZ73
Country: Slovenia
Krka’s basic line of business is the production and sale of prescription pharmaceuticals, non-prescription products and animal health products.
The company's focus is on the development of high-quality own-brand generic pharmaceuticals, which offer added value, and are marketed under Krka's own brands.
Our products are sold in over 70 countries. As part of our business strategy we have set the objective of balanced sales in five different regions: Slovenia, Central Europe, South-East Europe, East Europe, West Europe and Overseas Markets.
1954
Served areaWorldwide
Headcount12,600
HeadquartersŠmarješka cesta 6, 8000 Novo mesto – Slovenia
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 2,235,542,000.00 | 2,536,988,000.00 | 2,687,500,000.00 |
| Noncurrent Assets | N/A | 990,998,000.00 | 1,075,052,000.00 | 1,125,025,000.00 |
| Property Plant And Equipment | N/A | 807,824,000.00 | 773,657,000.00 | 779,336,000.00 |
| Deferred Tax Assets | N/A | 48,969,000.00 | 46,883,000.00 | 53,770,000.00 |
| Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income | N/A | 10,420,000.00 | 108,883,000.00 | 110,770,000.00 |
| Other Noncurrent Assets | N/A | 1,038,000.00 | 1,028,000.00 | 1,060,000.00 |
| Current Assets | N/A | 1,244,544,000.00 | 1,461,936,000.00 | 1,562,475,000.00 |
| Inventories | N/A | 453,690,000.00 | 455,707,000.00 | 553,332,000.00 |
| Current Trade Receivables | N/A | 383,560,000.00 | 467,764,000.00 | 402,730,000.00 |
| Other Current Receivables | N/A | 27,768,000.00 | 29,564,000.00 | 27,728,000.00 |
| Cash and cash equivalents | 218,667,000.00 | 313,568,000.00 | 159,838,000.00 | 518,934,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | 41,000.00 | 41,000.00 | 41,000.00 |
| Current Investments | N/A | 9,499,000.00 | 155,448,000.00 | 52,437,000.00 |
| Equity And Liabilities | N/A | 2,235,542,000.00 | 2,536,988,000.00 | 2,687,500,000.00 |
| Equity | 1,667,516,000.00 | 1,751,812,000.00 | 1,919,085,000.00 | 2,138,509,000.00 |
| Issued Capital | N/A | 54,732,000.00 | 54,732,000.00 | 54,732,000.00 |
| Retained Earnings | N/A | 1,684,285,000.00 | 1,819,937,000.00 | 1,996,246,000.00 |
| Treasury Shares | N/A | 99,279,000.00 | 114,541,000.00 | 124,566,000.00 |
| Other Reserves | N/A | 103,595,000.00 | 145,077,000.00 | 192,204,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 1,743,333,000.00 | 1,905,205,000.00 | 2,118,616,000.00 |
| Noncontrolling Interests | N/A | 8,479,000.00 | 13,880,000.00 | 19,893,000.00 |
| Liabilities | N/A | 483,730,000.00 | 617,903,000.00 | 548,991,000.00 |
| Noncurrent Liabilities | N/A | 172,796,000.00 | 162,674,000.00 | 132,130,000.00 |
| Noncurrent Provisions | N/A | 134,686,000.00 | 126,153,000.00 | 107,235,000.00 |
| Noncurrent Payables | N/A | 10,006,000.00 | 10,000,000.00 | 0.00 |
| Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities | N/A | N/A | 6,875,000.00 | 6,048,000.00 |
| Deferred Tax Liabilities | N/A | 11,179,000.00 | 10,922,000.00 | 10,758,000.00 |
| Current Liabilities | N/A | 310,934,000.00 | 455,229,000.00 | 416,861,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 107,116,000.00 | 130,011,000.00 | 140,837,000.00 |
| Current Contract Liabilities | N/A | 106,299,000.00 | 124,730,000.00 | 157,710,000.00 |
| Current Tax Liabilities Current | N/A | 15,748,000.00 | 7,023,000.00 | 28,194,000.00 |
| Other Current Liabilities | N/A | 79,059,000.00 | 190,032,000.00 | 86,368,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 1,534,941,000.00 | 1,565,802,000.00 | 1,717,453,000.00 |
| Other Revenue | 3,267,000.00 | 3,536,000.00 | 4,923,000.00 |
| Revenue From Contracts With Customers | 1,531,674,000.00 | 1,562,266,000.00 | 1,712,530,000.00 |
| Other Income | 10,495,000.00 | 11,376,000.00 | 9,197,000.00 |
| Profit Loss From Operating Activities | 390,744,000.00 | 354,788,000.00 | 381,211,000.00 |
| Finance Income | 23,259,000.00 | 19,711,000.00 | 57,668,000.00 |
| Finance Costs | 75,011,000.00 | 12,082,000.00 | 5,806,000.00 |
| Profit Loss Before Tax | 338,992,000.00 | 362,417,000.00 | 433,073,000.00 |
| Income Tax Expense Continuing Operations | 50,043,000.00 | 54,267,000.00 | 69,411,000.00 |
| Profit (loss) | 288,949,000.00 | 308,150,000.00 | 363,662,000.00 |
| Profit Loss Attributable To Owners Of Parent | 290,995,000.00 | 309,214,000.00 | 363,296,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 2,046,000.00 | -1,064,000.00 | 366,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 288,949,000.00 | 308,150,000.00 | 363,662,000.00 |
| Adjustments For Income Tax Expense | N/A | 50,043,000.00 | 54,267,000.00 | 69,411,000.00 |
| Adjustments For Finance Costs | N/A | 1,975,000.00 | 1,532,000.00 | 5,279,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -32,112,000.00 | -22,755,000.00 | -117,946,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -33,681,000.00 | 45,164,000.00 | 32,820,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 111,688,000.00 | 108,837,000.00 | 107,684,000.00 |
| Adjustments For Provisions | N/A | 1,572,000.00 | -2,647,000.00 | -4,272,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | -19,263,000.00 | 4,828,000.00 | -224,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 53,600,000.00 | 64,329,000.00 | 56,892,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 360,759,000.00 | 386,097,000.00 | 467,651,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 5,000.00 | 0.00 | N/A |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 516,000.00 | 3,700,000.00 | 4,949,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 74,806,000.00 | 65,914,000.00 | 87,905,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 6,017,000.00 | 6,213,000.00 | 6,827,000.00 |
| Cash Advances And Loans Made To Other Parties Classified As Investing Activities | N/A | N/A | 26,674,000.00 | 42,690,000.00 |
| Cash Receipts From Repayment Of Advances And Loans Made To Other Parties Classified As Investing Activities | N/A | N/A | 1,439,000.00 | 2,542,000.00 |
| Dividends Received Classified As Investing Activities | N/A | 575,000.00 | 668,000.00 | 631,000.00 |
| Interest Received Classified As Investing Activities | N/A | 2,144,000.00 | 718,000.00 | 3,115,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -109,594,000.00 | -372,637,000.00 | 76,414,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 25,505,000.00 | 15,262,000.00 | 10,025,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,086,000.00 | 3,515,000.00 | 3,926,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 133,283,000.00 | 155,907,000.00 | 175,044,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 247,000.00 | 366,000.00 | 4,179,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -154,609,000.00 | -169,850,000.00 | -187,022,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 96,556,000.00 | -156,390,000.00 | 357,043,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -1,655,000.00 | 2,660,000.00 | 2,053,000.00 |
| Cash and cash equivalents | 218,667,000.00 | 313,568,000.00 | 159,838,000.00 | 518,934,000.00 |
Please note that some sums might not add up.
SI0031102120
LEI549300H9RLRTRTLRUZ73
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustrySBI Top
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.